Study to evaluate different treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in genotype 3 HCV infected cirrhotic patients.

Trial Profile

Study to evaluate different treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in genotype 3 HCV infected cirrhotic patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms STEPS
  • Sponsors Roche
  • Most Recent Events

    • 01 Jun 2012 Primary endpoint 'Sustained-virological-response-rate' has been met.
    • 01 Jun 2012 Status changed from active, no longer recruiting to completed.
    • 12 Apr 2012 New source identified and integrated (EudraCT2007-002743-24: European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top